...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: More Exempt Distribution Investments

All the ongoing trials do cost Zenith some money..... They're not free. 

And according to the latest Financials and the MD&A they are also feeding Resverlogix along the way.

Most of the BODs and officers are being paid by way of deferred share units and restricted share units according to SEDI.

I know it's easy to be cynical about this company but we need to think positively and let this thing play out. We have no choice.

 

Koo

Share
New Message
Please login to post a reply